Published in Clin Cancer Res on June 01, 2004
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol (2007) 6.85
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano (2008) 2.76
Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging. Proc Natl Acad Sci U S A (2008) 2.16
Retracted Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol (2009) 2.12
Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. Nano Lett (2011) 1.92
NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer (2005) 1.87
Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res (2010) 1.83
Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A (2010) 1.64
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53
Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol Pharm (2009) 1.45
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci (2007) 1.41
Adding vitamin E-TPGS to the formulation of Genexol-PM: specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantly. PLoS One (2015) 1.39
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer (2007) 1.34
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm (2012) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano (2011) 1.20
Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol (2013) 1.16
Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release (2007) 1.15
Cancer wars: natural products strike back. Front Chem (2014) 1.11
Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med (2010) 1.07
Novel nanomaterials for clinical neuroscience. J Neuroimmune Pharmacol (2008) 1.07
Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther (2011) 1.06
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Advances of cancer therapy by nanotechnology. Cancer Res Treat (2009) 1.01
Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther (2012) 1.00
Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. Int J Nanomedicine (2010) 1.00
Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine (2013) 0.97
Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π-Π Stacking Stabilized Polymeric Micelles. ACS Nano (2015) 0.95
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs (2011) 0.94
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
Stereocomplexed poly(lactic acid)-poly(ethylene glycol) nanoparticles with dual-emissive boron dyes for tumor accumulation. ACS Nano (2010) 0.92
Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)-paclitaxel nanoparticles. Int J Nanomedicine (2011) 0.92
Self-assembled poly(butadiene)-b-poly(ethylene oxide) polymersomes as paclitaxel carriers. Biotechnol Prog (2007) 0.91
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol (2014) 0.91
Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. Clin Cancer Res (2015) 0.90
Polymeric core-shell assemblies mediated by host-guest interactions: versatile nanocarriers for drug delivery. Angew Chem Int Ed Engl (2009) 0.90
Controlled Drug Delivery: Historical perspective for the next generation. J Control Release (2015) 0.90
A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. J Pharm Sci (2009) 0.89
Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS One (2013) 0.88
Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer. J Nanobiotechnology (2011) 0.87
Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases. Biogerontology (2014) 0.87
Multi-drug delivery to tumor cells via micellar nanocarriers. Int J Pharm (2011) 0.86
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomedicine (2011) 0.86
Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol (2014) 0.86
Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release (2015) 0.86
Hydrophobic pharmaceuticals mediated self-assembly of beta-cyclodextrin containing hydrophilic copolymers: novel chemical responsive nano-vehicles for drug delivery. J Control Release (2010) 0.85
Highly stable, ligand-clustered "patchy" micelle nanocarriers for systemic tumor targeting. Nanomedicine (2010) 0.85
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther (2014) 0.85
Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model. BMC Cancer (2014) 0.84
Clinically relevant anticancer polymer Paclitaxel therapeutics. Cancers (Basel) (2010) 0.84
Fluorescence imaging enabled biodegradable photostable polymeric micelles. Adv Healthc Mater (2013) 0.84
A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety. J Biomed Biotechnol (2011) 0.84
Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release (2015) 0.83
Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. Biomed Res Int (2014) 0.83
Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. Dig Dis Sci (2014) 0.83
Core-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical Translation. Nano Today (2015) 0.83
Far-red light activatable, multifunctional prodrug for fluorescence optical imaging and combinational treatment. J Med Chem (2014) 0.83
Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res (2014) 0.82
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine (2015) 0.82
Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale (2013) 0.82
Cancer targeted therapeutics: From molecules to drug delivery vehicles. J Control Release (2015) 0.82
Augmenting drug-carrier compatibility improves tumour nanotherapy efficacy. Nat Commun (2016) 0.81
Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech (2014) 0.81
Nanotechnologies for noninvasive measurement of drug release. Mol Pharm (2013) 0.81
Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform. PLoS One (2014) 0.81
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small (2015) 0.80
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol (2008) 0.80
Nanomicellar carriers for targeted delivery of anticancer agents. Ther Deliv (2014) 0.80
Curcumin-loaded colloidal carrier system: formulation optimization, mechanistic insight, ex vivo and in vivo evaluation. Int J Nanomedicine (2015) 0.79
Preparation, pharmacokinetics, biodistribution, antitumor efficacy and safety of Lx2-32c-containing liposome. PLoS One (2014) 0.79
Optimization of Landscape Phage Fusion Protein-Modified Polymeric PEG-PE Micelles for Improved Breast Cancer Cell Targeting. J Nanomed Nanotechnol (2012) 0.79
Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors. Mol Cancer Ther (2014) 0.78
Nanomedicine in chemoradiation. Ther Deliv (2013) 0.78
Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide). Curr Opin Solid State Mater Sci (2012) 0.78
A target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer. J Cancer (2013) 0.78
Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. HPB (Oxford) (2011) 0.78
A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules. Arch Biochem Biophys (2016) 0.77
Investigation of endocytosis and cytotoxicity of poly-d, l-lactide-poly(ethylene glycol) micro/nano-particles in osteoblast cells. Int J Nanomedicine (2010) 0.77
Enhancement of the bioavailability of a novel anticancer compound (acetyltanshinone IIA) by encapsulation within mPEG-PLGA nanoparticles: a study of formulation optimization, toxicity, and pharmacokinetics. Oncotarget (2017) 0.75
Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila) (2014) 0.75
Nanomedicines for renal disease: current status and future applications. Nat Rev Nephrol (2016) 0.75
An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016). J Gynecol Oncol (2016) 0.75
Lx2-32c-loaded polymeric micelles with small size for intravenous drug delivery and their inhibitory effect on tumor growth and metastasis in clinically associated 4T1 murine breast cancer. Int J Nanomedicine (2016) 0.75
EFFECTS OF POLYMERIC NANOPARTICLE SURFACE PROPERTIES ON INTERACTION WITH BRAIN TUMOR ENVIRONMENT. Nano Life (2013) 0.75
Novel Nanoprinting for Oral Delivery of Poorly Soluble Drugs. Methodist Debakey Cardiovasc J (2016) 0.75
Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation. Int J Nanomedicine (2016) 0.75
Synthesis, characterization and drug loading property of Monomethoxy-Poly(ethylene glycol)-Poly(ε-caprolactone)-Poly(D,L-lactide) (MPEG-PCLA) copolymers. Sci Rep (2016) 0.75
Polyamide Nanogels from Generally Recognized as Safe Components and Their Toxicity in Mouse Preimplantation Embryos. Biomacromolecules (2015) 0.75
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. Cancer Res Treat (2014) 0.75
Synthesis, Structural Characterization, and Preclinical Efficacy of a Novel Paclitaxel-Loaded Alginate Nanoparticle for Breast Cancer Treatment. Int J Breast Cancer (2016) 0.75
The potential of polymeric micelles in the context of glioblastoma therapy. Front Pharmacol (2013) 0.75
Photodynamic therapy of tumors with pyropheophorbide-a-loaded polyethylene glycol-poly(lactic-co-glycolic acid) nanoparticles. Int J Nanomedicine (2016) 0.75
Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. Int J Nanomedicine (2017) 0.75
The preparation of metal-organic frameworks and their biomedical application. Int J Nanomedicine (2016) 0.75
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2005) 4.03
Virus-enabled synthesis and assembly of nanowires for lithium ion battery electrodes. Science (2006) 3.87
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.62
Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation (2005) 2.44
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol (2004) 2.44
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer (2008) 2.37
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol (2013) 2.14
Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol (2011) 2.09
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Chemotherapy use and associated factors among cancer patients near the end of life. Oncology (2007) 1.80
Effect of river landscape on the sediment concentrations of antibiotics and corresponding antibiotic resistance genes (ARG). Water Res (2006) 1.76
Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest (2004) 1.75
Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. Cancer (2004) 1.71
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res (2011) 1.69
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer (2007) 1.68
DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog (2008) 1.67
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer (2012) 1.58
MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res (2011) 1.54
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res (2006) 1.53
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer (2005) 1.52
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist (2014) 1.50
Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia Pac J Clin Oncol (2014) 1.49
Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. Thromb Res (2008) 1.48
Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters. Cancer Biol Ther (2006) 1.46
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. J Thorac Oncol (2015) 1.44
Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer (2007) 1.40
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). Leuk Lymphoma (2014) 1.40
Postoperative chemoradiotherapy of pancreatic cancer: what is the appropriate target volume of radiation therapy? Tumori (2006) 1.39
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol (2013) 1.39
Novel technique to appose flaps using the BioGlue in the external dacryocystorhinostomy. Ophthal Plast Reconstr Surg (2013) 1.39
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer (2008) 1.38
Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene (2003) 1.38
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene (2004) 1.38
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol (2002) 1.34
Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol (2008) 1.33
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther (2009) 1.32
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer (2012) 1.32
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol (2010) 1.31
Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One (2009) 1.30
Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol (2008) 1.29
Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology (2011) 1.29
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer (2007) 1.29
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene (2004) 1.25
Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology (2004) 1.25
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer (2013) 1.24
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood (2005) 1.24